Identification of Six Potential Markers for the Detection of Circulating Canine Mammary Tumour Cells in the Peripheral Blood Identified by Microarray Analysis

Costa, A. da; Lenze, Dido; Hummel, Michael; Kohn, Barbara; Gruber, Achim D.; Klopfleisch, Robert

doi:10.1016/j.jcpa.2011.06.004

Cited by 22 publications

(20 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, silencing αB-crystallin in these metastatic carcinoma cells reduced the viability of circulating tumor cells and suppressed lung metastases in orthotopic murine models of TNBC but had minimal or no impact on mammary tumor growth (Malin et al, 2015). Consistent with these findings, αB-crystallin is highly expressed in circulating tumor cells in canines with mammary tumors (da Costa et al, 2012). These results point to αB-crystallin as a key regulator of anoikis resistance and a promising target to activate anoikis and suppress metastasis by inhibiting its expression or antagonizing its function.…”

Section: Metastasis Enablersupporting

confidence: 57%

αB-crystallin: Portrait of a malignant chaperone as a cancer therapeutic target

Malin

Petrovič

Strekalova

et al. 2016

Pharmacology & Therapeutics

View full text Add to dashboard Cite

αB-crystallin is a widely expressed member of the small heat shock protein family that protects cells from stress by its dual function as a molecular chaperone to preserve proteostasis and as a cell death antagonist that negatively regulates components of the conserved apoptotic cell death machinery. Deregulated expression of αB-crystallin occurs in a broad array of solid tumors and has been linked to tumor progression and poor clinical outcomes. This review will focus on new insights into the molecular mechanisms by which oncogenes, oxidative stress, matrix detachment and other tumor microenvironmental stressors deregulate αB-crystallin expression. We will also review accumulating evidence pointing to an essential role for αB-crystallin in the multi-step metastatic cascade whereby tumor cells colonize distant organs by circumventing a multitude of barriers to cell migration and survival. Finally, we will evaluate emerging strategies to therapeutically target αB-crystallin and/or interacting proteins to selectively activate apoptosis and/or derail the metastatic cascade in an effort to improve outcomes for patients with metastatic disease.

show abstract

Section: Metastasis Enablersupporting

confidence: 57%

αB-crystallin: Portrait of a malignant chaperone as a cancer therapeutic target

Malin

Petrovič

Strekalova

et al. 2016

Pharmacology & Therapeutics

View full text Add to dashboard Cite

show abstract

“…Until now the usefulness and specificity of selected canine genes in CTC detection has been determined in mammary gland cancer cells from cell culture introduced into the blood. Moreover, some of these genes can also be used in quantitative PCR to predict the level of changes in the tumor (da Costa et al 2012).…”

Section: Methods Based On Nucleic Acidsmentioning

confidence: 99%

The application of circulating tumor cells detecting methods in veterinary oncology

Chmielewska¹,

Łosiewicz²,

Socha³

et al. 2013

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

Cancers are one of the most common diseases affecting dogs. Many of them develop spontaneously and their biology and histopathology shows many similarities to human cancers. What more, it is proved that there are much more analogies in molecular mechanisms of cancer development between these two species. Human oncology is seeking more and more efficient methods for an early disease detection which results directly in the extended life expectancy of patients affected. One of the most modern trends in the diagnosis of cancer is to detect circulating tumor cells (CTC) in the blood of patients. It is known that these cells are responsible for the formation of metastases in distant organs what results in the patient death. Moreover, it's confirmed that CTC are already present in patients' bloodstream in the early stages of tumor development. There is no doubt that mechanism of metastasis development in dogs is identical and thus the CTC are also present in their bloodstream. Despite the intense researches there is still no optimal method of isolating cancer cells from the blood where they occur extremely rarely. The purpose of this study is to analyze the implications of the detection methods of tumor cells in the blood in veterinary oncology.

show abstract

“…The first enabling steps have been made with the successful development of assays for the detection of circulating tumour cells (CTC) of canine mammary tumours and markers of minimal residual disease (MRD) for canine lymphomas (da Costa et al, 2011(da Costa et al, , 2012(da Costa et al, , 2013Sato et al, 2013). Sato et al (2013) convincingly showed that a real time monitoring approach using a PCRbased detection of sequences of the immunoglobulin heavy chain (IGH) gene fragment in the peripheral blood of the dogs with high grade B-cell lymphoma in the early phase of chemotherapy allows for the identification of minimal residual disease (MRD).…”

Section: Personalized Medicine In Veterinary Oncology: Where Are We?mentioning

confidence: 99%

“…In contrast, only CTCs of canine mammary tumours have been analysed so far in veterinary oncology (da Costa et al, 2011(da Costa et al, , 2012. The presence of these cells significantly correlated with the development of metastatic behaviour of canine mammary tumours (da Costa et al, 2013).…”

Section: Personalized Medicine In Veterinary Oncology: Where Are We?mentioning

confidence: 99%